Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It ...

Companies spend billions on programs that don’t pay off. Here’s how to fix that. by Michael Beer, Magnus Finnström and Derek Schrader Corporations are victims of the great training robbery. American ...

Chart does not reflect overnight price.

Training generative adversarial networks (GANs) with limited data generally results in deteriorated performance and collapsed models. To conquerthis challenge, we are inspired by the latest ...